JP7785669B2 - Ｎ末端ｓｃＦｖ多重特異性結合分子 - Google Patents

Ｎ末端ｓｃＦｖ多重特異性結合分子

Info

Publication number
JP7785669B2
JP7785669B2 JP2022525837A JP2022525837A JP7785669B2 JP 7785669 B2 JP7785669 B2 JP 7785669B2 JP 2022525837 A JP2022525837 A JP 2022525837A JP 2022525837 A JP2022525837 A JP 2022525837A JP 7785669 B2 JP7785669 B2 JP 7785669B2
Authority
JP
Japan
Prior art keywords
mbm
amino acids
domain
length
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553830A5 (enExample
JP2022553830A (ja
Inventor
シェン、ヤン
リー、アン－ウィー
ヤン、ヤン
リン、チャ－ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022553830A publication Critical patent/JP2022553830A/ja
Publication of JP2022553830A5 publication Critical patent/JP2022553830A5/ja
Priority to JP2025157633A priority Critical patent/JP2026016376A/ja
Application granted granted Critical
Publication of JP7785669B2 publication Critical patent/JP7785669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022525837A 2019-11-05 2020-11-04 Ｎ末端ｓｃＦｖ多重特異性結合分子 Active JP7785669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157633A JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930916P 2019-11-05 2019-11-05
US62/930,916 2019-11-05
PCT/US2020/058798 WO2021091953A1 (en) 2019-11-05 2020-11-04 N-terminal scfv multispecific binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157633A Division JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Publications (3)

Publication Number Publication Date
JP2022553830A JP2022553830A (ja) 2022-12-26
JP2022553830A5 JP2022553830A5 (enExample) 2023-11-13
JP7785669B2 true JP7785669B2 (ja) 2025-12-15

Family

ID=73598993

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525837A Active JP7785669B2 (ja) 2019-11-05 2020-11-04 Ｎ末端ｓｃＦｖ多重特異性結合分子
JP2025157633A Pending JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157633A Pending JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Country Status (12)

Country Link
US (3) US12240907B2 (enExample)
EP (1) EP4054646A1 (enExample)
JP (2) JP7785669B2 (enExample)
KR (1) KR20220093363A (enExample)
CN (1) CN114786730A (enExample)
AU (1) AU2020379735A1 (enExample)
BR (1) BR112022008552A2 (enExample)
CA (1) CA3157075A1 (enExample)
IL (1) IL292698A (enExample)
MX (1) MX2022005330A (enExample)
TW (1) TW202134277A (enExample)
WO (1) WO2021091953A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
CN114716548B (zh) * 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
BR112023022878A2 (pt) * 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
EP4585615A4 (en) * 2022-09-09 2026-07-08 Beijing Mabworks Biotech Co Ltd Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use
CN121002062A (zh) * 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
WO2025088587A1 (en) * 2023-10-27 2025-05-01 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2025240335A1 (en) * 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2026071855A1 (ko) * 2024-09-30 2026-04-02 주식회사 피노바이오 비대칭 항체를 포함하는 항체-이중 약물 접합체 및 이의 제조방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521759A (ja) 2009-03-25 2012-09-20 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ３抗体およびこれを用いた方法
JP2016525551A (ja) 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20170174769A1 (en) 2014-03-25 2017-06-22 Regeneron Pharmaceuticals, Inc. FGF21 Receptor Agonists And Uses Thereof
JP2018520987A (ja) 2015-04-29 2018-08-02 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
WO2019005640A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
JP2019525738A (ja) 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2511718B1 (en) 2009-12-07 2017-07-05 Ntt Docomo, Inc. Propagation path estimation method, program, and device
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
SG191233A1 (en) 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012158704A1 (en) * 2011-05-16 2012-11-22 Genentech, Inc. Fgfr1 agonists and methods of use
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
EP3107565A4 (en) 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
JP6993958B2 (ja) * 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
KR20180104148A (ko) 2016-02-05 2018-09-19 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
AU2018281280B2 (en) * 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN121591910A (zh) 2017-11-21 2026-03-03 诺华股份有限公司 针对肿瘤相关抗原的三特异性结合分子及其用途
JP7328990B2 (ja) * 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
WO2021150266A1 (en) 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
AU2021213767A1 (en) 2020-01-28 2022-07-28 Genentech, Inc. IL15/IL15R alpha heterodimeric Fc-fusion proteins for the treatment of cancer
EP4136119A4 (en) 2020-04-17 2024-09-11 Regeneron Pharmaceuticals, Inc. MODIFIED CCR POLYPEPTIDES AND USES THEREOF
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521759A (ja) 2009-03-25 2012-09-20 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ３抗体およびこれを用いた方法
JP2016525551A (ja) 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20170174769A1 (en) 2014-03-25 2017-06-22 Regeneron Pharmaceuticals, Inc. FGF21 Receptor Agonists And Uses Thereof
JP2018520987A (ja) 2015-04-29 2018-08-02 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
JP2019525738A (ja) 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
WO2019005640A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bart E.C.G. DE GOEIJ et al.，Molecular Cancer Therapeutics，2016年，15(11)，pp. 2688-2697
Rachel M. DEVAY et al.，Bioconjugate Chemistry，2017年，Vol. 28，pp. 1102-1114
Xiufeng WU et al.，Methods，2018年08月30日，Vol. 154，pp. 3-9

Also Published As

Publication number Publication date
TW202134277A (zh) 2021-09-16
KR20220093363A (ko) 2022-07-05
JP2026016376A (ja) 2026-02-03
US20250171545A1 (en) 2025-05-29
US20220251220A1 (en) 2022-08-11
MX2022005330A (es) 2022-05-26
US12649796B2 (en) 2026-06-09
IL292698A (en) 2022-07-01
BR112022008552A2 (pt) 2022-08-09
US12240908B2 (en) 2025-03-04
CN114786730A (zh) 2022-07-22
JP2022553830A (ja) 2022-12-26
WO2021091953A1 (en) 2021-05-14
EP4054646A1 (en) 2022-09-14
CA3157075A1 (en) 2021-05-14
US12240907B2 (en) 2025-03-04
AU2020379735A1 (en) 2022-05-26
US20210130477A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US12240908B2 (en) N-terminal scFv multispecific binding molecules
US20240383990A1 (en) Hinge-modified bispecific antibodies
JP2025026957A (ja) ＩＬ－１β受容体シグナル伝達に干渉する剤
TW202506728A (zh) 活化素a受體樣1型(alk1)之雙特異性促效性抗體
US20240247069A1 (en) Fgfr3 binding molecules and methods of use thereof
US20220372168A1 (en) Multispecific fgf21 receptor agonists and their uses
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
US20250011449A1 (en) Circularized antibody molecules
WO2025240335A1 (en) Fgfr3 binding molecules and methods of use thereof
WO2026044000A1 (en) Multispecific antibodies and methods of use thereof
KR20260013458A (ko) Il12 수용체에 대한 이중특이적 효현성 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251203

R150 Certificate of patent or registration of utility model

Ref document number: 7785669

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150